New ESMO guideline endorses PET/CT for bone imaging
Published on: August 13, 2020
A new European Society for Medical Oncology (ESMO) clinical practice guideline on Bone Health in Cancer has been published in Annals of Oncology, endorsing “FDG-PET-CT imaging as the most accurate way of assessing treatment response of hypermetabolic bone metastasis”.
Also, the new guideline recognizes that “metabolic treatment-induced effects appear much earlier than morphological changes and facilitate rapid treatment adaptation” when using FDG-PET/CT. Finally, the guideline states that NaF-PET/CT “is the most accurate osteotropic PET imaging agent; it is superior to 99mTc bone scintigraphy and SPECT and comparable to DW-MRI for diagnosis”.
Read more (open access):